[Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis]
Martínez Férez IM, Flores Moreno S, Rodríguez López R
Record ID 32013000640
Spanish
Authors' objectives:
The general objective:
To evaluate the therapeutic equivalence of interferon beta-1a, beta-1b, and glatiramer in the first-line treatment of patients with relapsing remitting multiple sclerosis.
Specific objectives:
To compare the relative efficacy of the two drugs through direct and indirect comparisons.
To evaluate the relative safety of the two drugs through direct and indirect comparisons.
Authors' recommendations:
High doses of the interferons Rebif and Betaferon result in a greater short-term efficacy in reducing attacks and recurrences than Avonex.
The available evidence does not permit us to reliably estimate the relative efficacy of Rebif as compared to Betaferon.
Copaxone, Rebif, and Betaferon exhibit no significant differences in efficacy in terms of risk of recurrence at 2 years.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_4_2013_InterferonGlatiramero_EM.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Humans
- Interferon-beta
- Multiple Sclerosis, Relapsing-Remitting
- Peptides
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.